Back to catalogue
№ 301 20 filings · 2021-07-27 → 2026-05-21

RECKITT BENCKISER GROUP PLC

RKT
Personal Care, Drug and Grocery Stores Share price 5,132p Market cap £32.6bn Overall fit 250 /1000

Defensive staple with no meaningful AI-receiver exposure, only moderate operating leverage, and a fair-not-cheap valuation. Doesn't fit the AI + long-tail-upside thesis; would sit as portfolio ballast at best.

Fair value range 4,800p–6,200p Mid case · £34.9bn
Absolute upside +7.2% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean, well-disclosed financials with detailed segmental reporting
  • Multiple valuation approaches (forward P/E, sum-of-parts) converge on similar range
  • Central case is close to current price, so directional call is modest
Limits the call
  • NEC litigation exposure is unquantifiable and could be material
  • MJN Nutrition terminal value uncertain given portfolio review and birth-rate headwinds
Methodology

Forward P/E on FY2026e adj EPS with sum-of-parts cross-check

In one line · bull case

Portfolio simplification is complete and Core Reckitt is now delivering mid-single-digit LFL growth with expanding margins at a fair valuation.

In one line · biggest risk

US NEC (Necrotizing Enterocolitis) infant-formula litigation could crystallise a material and unquantifiable liability against Mead Johnson.

Drivers
AI beneficiary 8 /100
Consumer staples company; no AI revenue, no AI-linked TAM expansion, only AI as internal productivity user.
Operating leverage 40 /100
60.7% gross margin but BEI and most costs scale with volume; ~1.5-2x flow-through, not step-change.
Earnings vs expectations 45 /100
Broadly meets guidance with occasional MJN-driven misses; more downside than upside surprises historically.
Growth momentum 60 /100
Core Reckitt re-accelerating: Q3 2025 LFL +6.7%, volumes +3.4%, all categories/regions in growth; medium-term guide +4-5%.
Moat 65 /100
Strong Powerbrands (Dettol, Lysol, Durex, Finish, Nurofen) with real pricing power and category leadership; not dominant network effects.
Earnings quality 60 /100
Adjusted EPS runs 25-40% above IFRS due to recurring impairments (IFCN, Biofreeze) and adjusting items; FCF conversion 91-97%.
Management quality 50 /100
Three CEOs in five years and a 2023 trade-spend accounting issue in the Middle East limit the track record; Licht now delivering.
Cyclicality 15 /100
Highly defensive category mix (hygiene, OTC medicines, intimate wellness, infant nutrition) with low economic sensitivity.
Leverage 45 /100
Net debt 2.0x EBITDA at end-2024, but £1.6bn special dividend Feb-2026 and ongoing buyback signal management comfort; A-grade credit target intact.
Value-trap signals · 4
  • Repeated goodwill/intangible impairments in Nutrition (IFCN) and Biofreeze
  • NEC litigation with unquantifiable potential outflow
  • Three CEOs in five years plus 2023 Middle East trade-spend accounting understatement
  • MJN 'evaluating opportunities' language suggests further portfolio separation possible

RECKITT BENCKISER GROUP PLC (RKT) — Research Note

Executive summary

Reckitt is a UK-listed consumer health and hygiene company with 11 "Powerbrands" (Dettol, Lysol, Durex, Finish, Nurofen, Gaviscon, Mucinex, Vanish, Harpic, Veet, Strepsils) plus Mead Johnson infant nutrition, having just divested Essential Home to Advent (Dec 2025) and returned £1.6bn via special dividend (Feb 2026). Operating trajectory has inflected — from the demand-normalisation drag of 2022-24, Core Reckitt is now delivering broad-based mid-single-digit growth (Q3 2025 LFL +6.7%, YTD +5.0%) with 140bps of margin expansion in FY2024 and further margin gains expected in FY2025 from the Fuel for Growth programme 2025-10-22 Q3 update; 2025-03-06 FY2024 results. The single most important point for valuation: this is a defensive staple with re-accelerating organic growth trading on a modest low-teens P/E — a fair-value name, not obviously cheap or expensive, and structurally unrelated to AI spending.

Fair value estimate

  • Range: 4,800p – 6,200p per share → implied market cap £30.5bn – £39.4bn
  • Midpoint: ~5,500p per share (£34.9bn mcap) → c.+7% upside to current £32.5bn
  • Methodology: forward P/E multiple applied to FY2026 adjusted EPS. Working: FY2024 adj diluted EPS 349.0p; guidance points to further FY2025 EPS growth on Core LFL of ~4%+, cost programme delivery and share consolidation (24-for-25) tailwind. FY2026 adj EPS estimated 360-380p post-Essential Home exit and buyback. Applied peer-relevant P/E range of 13.5x-17x reflecting the mid-tier staples multiple (below Unilever/Procter & Gamble, in line with re-rated GSK consumer health equivalents). Sum-of-parts check: Core Reckitt (£11bn revenue at ~26% adj op margin = £2.85bn) at 18x post-tax and MJN (£2.1bn revenue at ~19% margin) at ~10x post-tax gives similar ~£33-36bn equity value 2025-03-06 FY2024 results; 2025-10-22 Q3 update; 2026-01-07 special dividend circular.

Sector context

  • Confirmed: Consumer Staples / Personal Care, Drug and Grocery Stores.
  • Peers: Unilever (ULVR), Procter & Gamble (PG US), Colgate-Palmolive (CL US), Haleon (HLN — direct comparable in consumer health), Kenvue (KVUE US).
  • Quality/growth/leverage profile is broadly in line with typical staples peers but a step below the top tier. Growth momentum now competitive (Core Reckitt LFL 3-year CAGR of +5% 2025-03-06 FY2024 results); gross margin 60.7% and adj op margin 24.5% are respectable; net debt of 2.0x EBITDA is at the higher end but manageable and improving as the buyback and special dividend show balance-sheet confidence.

Investment thesis (3 bullets)

  • Portfolio simplification is now largely complete and Core Reckitt is delivering. Essential Home divested (Dec 2025), £1.6bn returned via special dividend (Feb 2026), £1bn buyback underway; Core Reckitt Q3 2025 LFL +6.7% with volumes +3.4%, all four categories in growth and Emerging Markets +15.5% 2025-10-22 Q3 update; 2026-01-07 special dividend circular. The narrative of "self-help + broken portfolio" is transitioning to "focused Powerbrand growth engine".
  • Margin trajectory is intact. FY2024 adj op margin expanded +140bps to 24.5% with fixed costs down 90bps; Fuel for Growth targets a further 300bps fixed-cost reduction by 2027 (from ~22% to ~19% of net revenue) — highly visible margin lever 2025-03-06 FY2024 results; 2024-10-23 Q3 2024 update.
  • Defensive cash generation with credible capital returns. £2.2bn FCF in FY2024 despite Nutrition rebasing; £2.7bn returned to shareholders in 2024, dividend +5%, plus £1.6bn special and ongoing buybacks. Strong brand portfolio, favourable emerging-market mix (39% of Core) and low cyclicality provide downside protection 2025-03-06 FY2024 results; 2026-05-21 AGM results.

Key risks (3 bullets)

  • NEC (Necrotizing Enterocolitis) litigation on Mead Johnson infant formula. Multi-district litigation ongoing in US federal and state courts; one trial resulted in a $60m verdict (2024, under appeal), one favourable verdict; management explicitly says "possible economic outflow cannot be reliably estimated, but may be significant" 2025-03-06 FY2024 results, Note 9. Insurance may partially mitigate but tail risk is real and could impact any future MJN carve-out valuation.
  • IFCN goodwill/regulatory pressure. £696m IFCN impairment in 2024 (on top of £810m in 2023) reflects increased US regulatory capital requirements and supply-chain resilience investment. Zero headroom to recoverable amount at year-end — further impairments possible on any deterioration 2025-03-06 FY2024 results, Note 6.
  • Consumer staples multiple risk / execution. Core Reckitt growth was flattered in Q3 2025 by Mead Johnson lapping the 2024 Mount Vernon tornado (MJN +22% LFL vs -17.4% prior year); underlying trend is more modest. If mid-4% Core LFL growth disappoints or if bond yields stay elevated, the sector multiple could compress 2025-10-22 Q3 update.

Operating leverage

Reckitt has moderate operating leverage, typical of a branded consumer goods company. Gross margin of 60.7% (FY2024) is high — meaning incremental revenue drops meaningfully to gross profit — but the majority of the cost base scales with volume: cost of sales £5.6bn on £14.2bn revenue, and brand equity investment (BEI) sits at 13.4% of net revenue and is being actively increased to fund innovation. The genuinely fixed portion is c.20.9% of net revenue in "fixed costs" (headed to c.19% via Fuel for Growth) 2025-03-06 FY2024 results. Sensitivity: a 10-20% revenue beat would likely add ~15-30% to operating profit (roughly 1.5-2x flow-through), not multiples of profit. There is no obvious inflection point akin to a SaaS gross-margin curve or a capacity-constrained asset. The Powerbrand model does create some price/mix leverage — Q3 2025 Core Reckitt achieved +3.3% price/mix with +3.4% volume, and Intimate Wellness took +10.9% price/mix — but this is incremental, not step-change. This is not a "surprise measured in multiples of profit" business.

Value-trap signals

  • Nutrition (MJN) structural questions: repeated impairments (£810m in 2023, £696m in 2024, £142m Biofreeze), a competitor supply shortage in 2022 that flattered results, the 2024 tornado disruption, and NEC litigation. IFCN Chinese business divested in 2021 at a large loss. Management is "evaluating opportunities for MJN" — signalling possible further separation.
  • Long history of governance/strategy churn: three CEOs in ~5 years (Rakesh Kapoor → Laxman Narasimhan → Nicandro Durante → Kris Licht), Q4 2023 trade-spend accounting understatement in two Middle East markets (£55m revenue impact, disciplinary action taken).
  • Lysol/Dettol structural rebasing from COVID peaks is now largely done but was a multi-year headwind that hurt the equity story.
  • These are legitimate concerns but do not point to terminal decline — the underlying category positions are strong. Not classified as a value trap, but the discount to top-tier staples peers is earned.

Earnings vs. expectations

Across the 2023-2025 filings, Reckitt has broadly met or slightly beaten guidance at the group level, with notable execution issues in Nutrition. Highlights: (a) FY2024 delivered +1.4% LFL, at guidance midpoint; adj EPS +7.9% vs "adj EPS growth" guidance — met; (b) H1 2024 guidance cut from +2-4% to +1-3% Group LFL following the July 2024 Mount Vernon tornado — a miss driven by external event; (c) FY2023 delivered +3.5% LFL, in the +3-5% range; (d) Q4 2023 disappointed on the £55m Middle East trade-spend accounting adjustment; (e) FY2025 guidance of +3-4% Group LFL and Core +4%+ maintained through Q3, with Q3 LFL +7.0% actually running ahead. Overall: mostly meets, some misses, occasional beats — call it a "meets" track record with more downside surprises than upside, largely reflecting the MJN volatility.

Conviction: 3 (moderate)

What anchors it: (i) clean, well-audited financials with detailed segmental disclosure; (ii) the current price is close to my central case, so I am not making an aggressive directional call; (iii) multiple valuation methods (forward P/E, sum-of-parts) converge on a similar range. What limits it: (i) NEC litigation is genuinely unquantifiable — tail risk could materially alter fair value; (ii) MJN's terminal value is uncertain given portfolio-review commentary and structural birth-rate headwinds; (iii) applying a staples multiple assumes multiple stability, which is sensitive to rates and to Reckitt closing the growth/quality gap vs Unilever/PG.

Overall score: 250/1000

This is a defensive, fair-value consumer staples name that has no meaningful AI exposure, limited operating leverage, and adequate but not spectacular downside protection. It scores well below the strategy's core buckets. It could sit in a portfolio as ballast, but does not fit the "AI-receiver + long-tail upside" thesis this investor is building.

Filings consulted · 22

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-21Result OF Agm2026-05-21_9580979_result-of-agm.md0.30
  2. 2026-03-25Annual Financial Report And Notice OF Agm2026-03-25_9491887_annual-financial-report-and-notice-of-agm.md0.30
  3. 2026-01-07Special Dividend And Share Consolidation2026-01-07_9337660_special-dividend-and-share-consolidation.md0.26
  4. 2025-10-22Reckitt Q3 2025 Trading Update2025-10-22_9185823_reckitt-q3-2025-trading-update.md0.72
  5. 2025-05-08Result OF Agm2025-05-08_8868759_result-of-agm.md0.20
  6. 2025-03-26Annual Financial Report And Notice OF Agm2025-03-26_8798267_annual-financial-report-and-notice-of-agm.md0.20
  7. 2025-03-06Final Results2025-03-06_8765645_final-results.md0.65
  8. 2024-10-23Reckitt Q3 2024 Trading Update2024-10-23_8502572_reckitt-q3-2024-trading-update.md0.55
  9. 2024-07-24Half Year Report2024-07-24_8327297_half-year-report.md0.41
  10. 2024-05-02Result OF Agm2024-05-02_8171564_result-of-agm.md0.14
  11. 2024-02-28Final Results2024-02-28_8059644_final-results.md0.45
  12. 2023-10-25Q3 Trading Statement2023-10-25_7837137_q3-trading-statement.md0.38
  13. 2023-07-26Half Year Report2023-07-26_7654905_half-year-report.md0.23
  14. 2023-05-03Result OF Agm2023-05-03_7511537_result-of-agm.md0.07
  15. 2023-04-26Q1 Trading Statement2023-04-26_4375_q1-trading-statement.md0.21
  16. 2023-03-22Annual Financial Report And Notice OF Agm2023-03-22_7277598_annual-financial-report-and-notice-of-agm.md0.07
  17. 2023-03-01Final Results2023-03-01_7281640_final-results.md0.25
  18. 2022-07-27Half Year Results2022-07-27_7179692_half-year-results.md0.23
  19. 2022-05-20Result OF Agm2022-05-20_6972687_result-of-agm.md0.07
  20. 2022-04-27Notice OF Agm2022-04-27_7087350_notice-of-agm.md0.07
  21. 2021-09-23Trading Update Amp Launch OF Investor Seminar Series2021-09-23_6557505_trading-update-amp-launch-of-investor-seminar-series.md0.21
  22. 2021-07-27Half Year Report2021-07-27_6744278_half-year-report.md0.09

This research note was authored by a large language model after reading 20 regulatory filings published between 2021-07-27 and 2026-05-21. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.